Literature DB >> 22160016

Therapy for aplastic anemia.

Amy E DeZern1, Eva C Guinan.   

Abstract

A 24-year-old man from Ecuador presents to your clinic with dyspnea on exertion, bruising, and petechiae. He is noted to be pancytopenic with ANC 430, hemoglobin 7.4 g/dL (reticulocyte count 0.9%), and platelets 18 000. His BM biopsy is hypocellular for age. Ultimately, he is diagnosed with severe aplastic anemia. He is the only child of 2 South American parents without any matches in the unrelated donor registry, including cord blood. He is red cell- and platelet transfusion-dependent. He has been recommended therapy with antithymocyte globulin and cyclosporine but declined it. He seeks recommendations about new alternatives to this regimen to improve his chance of response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160016      PMCID: PMC4138693          DOI: 10.1182/asheducation-2011.1.82

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  12 in total

1.  High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial.

Authors:  J F Tisdale; D E Dunn; N Geller; M Plante; O Nunez; C E Dunbar; A J Barrett; T J Walsh; S J Rosenfeld; N S Young
Journal:  Lancet       Date:  2000-11-04       Impact factor: 79.321

2.  Danazol as first-line therapy for aplastic anemia.

Authors:  José Carlos Jaime-Pérez; Perla R Colunga-Pedraza; Cynthia D Gómez-Ramírez; César H Gutiérrez-Aguirre; Olga G Cantú-Rodríguez; Luz C Tarín-Arzaga; David Gómez-Almaguer
Journal:  Ann Hematol       Date:  2011-01-29       Impact factor: 3.673

Review 3.  Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going.

Authors:  Antonio M Risitano
Journal:  Br J Haematol       Date:  2010-12-01       Impact factor: 6.998

4.  Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study.

Authors:  Phillip Scheinberg; Colin O Wu; Olga Nunez; Priscila Scheinberg; Carol Boss; Elaine M Sloand; Neal S Young
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

Review 5.  ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia--systematic review and meta-analysis.

Authors:  Anat Gafter-Gvili; Ron Ram; Ronit Gurion; Mical Paul; Moshe Yeshurun; Pia Raanani; Ofer Shpilberg
Journal:  Acta Haematol       Date:  2009-02-25       Impact factor: 2.195

Review 6.  Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis.

Authors:  Ronit Gurion; Anat Gafter-Gvili; Mical Paul; Liat Vidal; Isaac Ben-Bassat; Moshe Yeshurun; Ofer Shpilberg; Pia Raanani
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

7.  Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.

Authors:  Antonio Maria Risitano; Carmine Selleri; Bianca Serio; Giovanni Fernando Torelli; Alexander Kulagin; Sébastien Maury; Jörg Halter; Vikas Gupta; Andrea Bacigalupo; Gerard Sociè; André Tichelli; Hubert Schrezenmeier; Judith Marsh; Jakob Passweg; Bruno Rotoli
Journal:  Br J Haematol       Date:  2009-12-07       Impact factor: 6.998

8.  Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil.

Authors:  Phillip Scheinberg; Olga Nunez; Colin Wu; Neal S Young
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

9.  High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up.

Authors:  Robert A Brodsky; Allen R Chen; Donna Dorr; Ephraim J Fuchs; Carol Ann Huff; Leo Luznik; B Douglas Smith; William H Matsui; Steven N Goodman; Richard F Ambinder; Richard J Jones
Journal:  Blood       Date:  2009-12-16       Impact factor: 22.113

10.  Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children.

Authors:  Abdulrahman Alsultan; Neil A Goldenberg; Nicole Kaiser; Douglas K Graham; Taru Hays
Journal:  Pediatr Blood Cancer       Date:  2009-05       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.